5-Methoxy-7-nitro-1lambda~6~,2,4-benzothiadiazine-1,1,3(2H,4H)-trione | 820214-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 英文名称: 5-Methoxy-7-nitro-1lambda~6~,2,4-benzothiadiazine-1,1,3(2H,4H)-trione
• 英文别名: 5-methoxy-7-nitro-1,1-dioxo-4H-1λ6,2,4-benzothiadiazin-3-one
• CAS: 820214-19-5
• 化学式: C₈H₇N₃O₆S
• 分子量: 273.226
• InChiKey: WNQJEGXTWBZCMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  139
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-Methoxy-7-nitro-1lambda~6~,2,4-benzothiadiazine-1,1,3(2H,4H)-trione 在 吡啶 、 lithium chloride 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 3-[(2-chlorophenyl)amino]-7-nitro-4H-1,2,4-benzothiadiazin-5-ol 1,1-dioxide
  参考文献：
  名称：

  3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists

  摘要：

  A series of 3-arylamino-2H-1,2,4-benzothiadiazin-5-oI 1,1-dioxides were prepared and shown to be novel and selective antagonists of the CXCR2 receptor. Synthesis, structure and activity relationships, selectivity, and some developability properties are described. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.011
• 作为产物：
  描述：

  氯磺酰异氰酸酯 、 2-甲氧基-4-硝基苯胺 在 三氯化铝 作用下， 以 various solvent(s) 为溶剂， 生成 5-Methoxy-7-nitro-1lambda~6~,2,4-benzothiadiazine-1,1,3(2H,4H)-trione
  参考文献：
  名称：

  3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists

  摘要：

  A series of 3-arylamino-2H-1,2,4-benzothiadiazin-5-oI 1,1-dioxides were prepared and shown to be novel and selective antagonists of the CXCR2 receptor. Synthesis, structure and activity relationships, selectivity, and some developability properties are described. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.011

文献信息

• Il-8 receptor antagonists
  申请人：Busch-Petersen Jakob

  公开号：US20060122173A1

  公开（公告）日：2006-06-08

  This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  本发明涉及公式(I)到(VII)的新化合物及其组合物，用于治疗由趋化因子白介素8（IL-8）介导的疾病状态。
• IL-8 RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1631559A2

  公开（公告）日：2006-03-08
• EP1631559A4
  申请人：——

  公开号：EP1631559A4

  公开（公告）日：2008-08-27
• [EN] IL-8 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR IL-8
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005000231A2

  公开（公告）日：2005-01-06

  This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).